Lab
Myrna Liz Beltran
Myrna Liz Beltran was paid $3.00M by Medicaid between Jan 2018 and Dec 2024, across 73 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 16% of everything it billed.
33Billing provider infoMYRNA LIZ BELTRAN
NAGUABO, PR 00718
NAGUABO, PR 00718
33aNPI1659323178assigned 05/16/2006
33bProvider typeClinical Medical Laboratory
28Total paid$3.00M
24GClaims226,841
24DCodes billed73
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#24 of 777
Median peer was paid$278K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,598 | $145K | |
| 2019 | 30,622 | $231K | |
| 2020 | 22,991 | $290K | |
| 2021 | 34,975 | $653K | |
| 2022 | 36,089 | $656K | |
| 2023 | 33,733 | $439K | |
| 2024incomplete | 45,833 | $585K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 16% | 11,253 | 9,690 | $480K |
| 84443 | Thyroid stimulating hormone (TSH) | 10% | 18,346 | 15,881 | $314K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 9.1% | 11,217 | 10,108 | $272K |
| 80061 | Lipid panel | 8.4% | 18,250 | 15,914 | $253K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7.7% | 4,594 | 4,336 | $230K |
| 80053 | Comprehensive metabolic panel | 6.9% | 18,907 | 16,294 | $207K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.2% | 28,029 | 23,703 | $187K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.3% | 4,950 | 4,332 | $128K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.2% | 9,798 | 8,533 | $96K |
| 87276 | 2.5% | 6,840 | 5,770 | $75K | |
| 86738 | 2.4% | 6,147 | 5,262 | $71K | |
| 81000 | 2.4% | 21,421 | 18,434 | $71K |
61 more codes
| 87275 | 2.3% | 6,836 | $70K | |
| 84439 | 1.7% | 6,232 | $50K | |
| 82274 | 1.4% | 3,242 | $43K | |
| 86328 | 1.1% | 1,718 | $34K | |
| 86701 | 1.1% | 4,210 | $34K | |
| 87088 | <1% | 3,265 | $28K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 816 | $27K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 517 | $27K |
| 82043 | <1% | 5,347 | $26K | |
| 82607 | <1% | 1,814 | $25K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,067 | $25K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 719 | $24K |
| 84153 | <1% | 1,456 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,004 | $20K |
| 80074 | <1% | 351 | $16K | |
| 84436 | <1% | 2,510 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,598 | $13K |
| 86592 | <1% | 3,385 | $13K | |
| 84479 | <1% | 2,296 | $12K | |
| 85027 | <1% | 1,904 | $11K | |
| 86803 | <1% | 677 | $9K | |
| 87490 | <1% | 403 | $7K | |
| 82570 | <1% | 1,297 | $6K | |
| 87590 | <1% | 343 | $6K | |
| 85651 | <1% | 1,595 | $5K | |
| 85730 | <1% | 832 | $4K | |
| 82951 | <1% | 355 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 52 | $4K |
| 86769 | <1% | 85 | $3K | |
| 87899 | <1% | 252 | $3K | |
| 84703 | <1% | 537 | $3K | |
| 85610 | <1% | 806 | $3K | |
| 83001 | <1% | 138 | $2K | |
| 86038 | <1% | 169 | $2K | |
| 84550 | <1% | 329 | $1K | |
| 82950 | <1% | 308 | $1K | |
| 83002 | <1% | 71 | $1K | |
| 83540 | <1% | 200 | $1K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 1,017 | $1K |
| 83655 | <1% | 96 | $1K | |
| 82947 | <1% | 316 | $1K | |
| 86696 | <1% | 45 | $861.35 | |
| 84146 | <1% | 46 | $829.34 | |
| 80050 | General health panel | <1% | 121 | $820.31 |
| 87177 | <1% | 132 | $788.97 | |
| 86140 | <1% | 137 | $634.61 | |
| 84702 | <1% | 46 | $604.07 | |
| 86695 | <1% | 30 | $396.28 | |
| 82746 | <1% | 30 | $387.34 | |
| 82728 | <1% | 29 | $371.47 | |
| 87340 | <1% | 24 | $246.96 | |
| 84160 | <1% | 34 | $190.74 | |
| 86900 | <1% | 39 | $115.53 | |
| 86901 | <1% | 39 | $115.53 | |
| 81001 | <1% | 30 | $114.30 | |
| 84460 | <1% | 52 | $83.57 | |
| 82565 | <1% | 15 | $71.68 | |
| 86886 | <1% | 13 | $62.11 | |
| 86430 | <1% | 21 | $51.03 | |
| 84450 | <1% | 24 | $44.04 | |
| 87084 | <1% | 17 | $29.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBELTRAN, MYRNA (OWNER)
| Provider | Location | Paid |
|---|---|---|
| MB Clinical Laboratories Corp. | Naguabo, PR | $1.30M |
| Myrna Liz Beltran | Carolina, PR | $222K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.